MicroRNAs as Bile-based Biomarkers in Pancreaticobiliary Cancers

CompletedOBSERVATIONAL
Enrollment

229

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

March 11, 2020

Study Completion Date

July 27, 2020

Conditions
Pancreatic CancerCholangiocarcinomaAmpullary CancerBiliary StrictureGallstone Disease
Interventions
DIAGNOSTIC_TEST

Small RNA Sequencing and Validation of candidate miRNAs

Samples were prepared for small RNA sequencing using Qiagen's QIAseq small RNA Library Prep kit, quality controlled using an Agilent Bioanalyzer 2100 and sequenced on an NextSeq 500 system (Illumina, San Diego, USA) using the default single-end 75 base pair protocol to include integrated unique molecular indices (UMIs). Validation was undertaken using Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) either using target-specific stem-loop primer assays (TaqMan) or universal reverse transcription (RT) and locked nucleic acid (LNA) enhanced specific primers with SYBR green I assay detection

Trial Locations (1)

W12 0HS

Imperial College Healthcare NHS Trust, London

All Listed Sponsors
collaborator

Royal Surrey County Hospital NHS Foundation Trust

OTHER

collaborator

Royal Free Hospital NHS Foundation Trust

OTHER

lead

Imperial College London

OTHER

NCT06258824 - MicroRNAs as Bile-based Biomarkers in Pancreaticobiliary Cancers | Biotech Hunter | Biotech Hunter